Akero Therapeutics - Biotech Company Impresses with Strong Pipeline, Takeover Speculations Cause Stock Surge!
Reading Time: 1 minute
Business Driver: The biotech company Akero Therapeutics (AKRO) specializes in developing new therapies and preparations for treating metabolic diseases such as metabolic-associated steatohepatitis (MASH). With Efruxifermin (EFX), they have a promising candidate in the advanced stage of clinical trials. Recently, they published encouraging data from the 'Phase IIb SYMMETRY' study. Akero Therapeutics has recently come into the spotlight of investors in connection with takeover speculation. According to a report by StreetInsider on May 20, Akero...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
